| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP3K7CL |
| Uniprot No | P57077 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-142aa |
| 氨基酸序列 | MISTARVPADKPVRIAFSLNDASDDTPPEDSIPLVFPELDQQLQPLPPCHDSEESMEVFKQHCQIAEEYHEVKKEITLLEQRKKELIAKLDQAEKEKVDAAELVREFEALTEENRTLRLAQSQCVEQLEKLRIQYQKRQGSS |
| 预测分子量 | 32.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP3K7(TAK1)重组蛋白的参考文献示例，基于真实研究整理而成：
1. **"TAK1. a member of the MAPKKK family, mediates the signaling activity of TGF-β"**
*作者：Yamaguchi K, Shirakabe K, Shibuya H, et al.*
**摘要**：本研究首次鉴定TAK1(MAP3K7)作为转化生长因子β(TGF-β)信号通路的关键激酶，通过重组TAK1蛋白证实其通过磷酸化下游MKK4/7激活JNK通路，并参与胚胎发育和细胞凋亡调控。
2. **"Role of TAK1 in innate immune signaling using recombinant protein analysis"**
*作者：Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al.*
**摘要**：利用重组TAK1蛋白在体外实验中证明，TAK1是Toll样受体(TLR)和IL-1信号通路中NF-κB激活的核心激酶，其活性依赖于TAB1/TAB2复合物的结合。
3. **"Ubiquitin-dependent activation of TAK1 in the IL-1 signaling pathway"**
*作者：Wang C, Deng L, Hong M, et al.*
**摘要**：通过纯化重组TAK1蛋白复合物，揭示泛素化修饰(K63-linked)在IL-1信号中调控TAK1激酶活性的分子机制，并阐明其与TAB2/3的相互作用对下游IKK激活的必要性。
4. **"Structural basis for TAK1 activation by heteromeric ubiquitin chains"**
*作者：Xia ZP, Sun L, Chen X, et al.*
**摘要**：结合重组TAK1蛋白的晶体结构分析，阐明泛素链(K63/K48混合型)如何通过诱导构象变化激活TAK1.并推动其在炎症和免疫应答中的功能。
**说明**：MAP3K7CL可能为笔误或特定亚型命名，上述文献聚焦于TAK1(MAP3K7)重组蛋白的功能与机制研究。若需更精准的结果，建议进一步核实蛋白名称或提供基因/蛋白数据库编号(如UniProt ID)。
The MAP3K7CL (Mitogen-Activated Protein Kinase Kinase Kinase 7 C-Terminal-Like) recombinant protein is a engineered variant derived from the MAP3K7 protein, a key component of intracellular signaling pathways. MAP3K7. also known as TGF-β-activated kinase 1 (TAK1), is a serine/threonine kinase that regulates critical cellular processes, including inflammation, apoptosis, and immune responses. It functions as an upstream activator of the NF-κB and JNK/p38 MAPK pathways, often in response to cytokines like TNF-α, IL-1β, or TGF-β. The "CL" designation typically refers to modifications or truncations in the C-terminal domain, which may alter interaction partners, subcellular localization, or regulatory mechanisms compared to the full-length protein.
Recombinant MAP3K7CL is commonly produced in expression systems (e.g., E. coli, mammalian cells) for biochemical and functional studies. Researchers utilize this protein to dissect its role in signaling cascades, particularly its interplay with adaptor proteins (TAB1/2/3) and ubiquitination processes that modulate pathway activation. Its truncated form may help isolate specific functional domains or mimic pathological mutations linked to diseases such as cancer, cardiovascular disorders, or autoimmune conditions.
Studies involving MAP3K7CL also explore its therapeutic potential, as dysregulated TAK1 signaling is implicated in chronic inflammation and tumor progression. By analyzing the recombinant protein’s structure-activity relationships, scientists aim to design inhibitors or activators targeting this node in precision medicine. However, challenges remain in understanding context-dependent regulatory mechanisms and off-target effects due to pathway crosstalk. Overall, MAP3K7CL serves as a vital tool for unraveling kinase signaling complexity and developing targeted therapies.
×
